Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
Rhea-AI Summary
Sagimet Biosciences (Nasdaq: SGMT) will present a poster at the 10th Annual MASH-TAG Conference held January 8-10, 2026 in Park City, Utah.
The poster reports a secondary analysis from the Phase 2b FASCINATE-2 trial showing that denifanstat elicited a significant ≥2-stage fibrosis improvement in F3 MASH patients and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients. Presenting author is Rohit Loomba, M.D., M.H.Sc. Poster number MASHTAG.2026.A23 will be presented on Saturday, January 10, 2026 at The Chateaux Deer Valley.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, SGMT gained 0.91%, reflecting a mild positive market reaction. Argus tracked a peak move of +12.8% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $213M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SGMT was up 1.1% while peers were mixed: ACIU +6.36%, NMRA +10.1%, PRQR +4.35%, SLN +1.4%, THRD -0.55%, suggesting more stock-specific than sector-driven trading.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 18 | Clinical PK data | Positive | -4.9% | Positive Phase 1 PK results for denifanstat and resmetirom combination. |
| Dec 17 | License agreement | Positive | +3.6% | Exclusive global license for innovative resmetirom API forms. |
| Dec 10 | China NDA update | Positive | +0.6% | China NMPA acceptance of NDA for denifanstat in moderate to severe acne. |
| Dec 10 | Phase 3 acne data | Positive | +0.6% | Phase III acne trial met all primary and key secondary endpoints. |
| Dec 09 | Inducement grants | Neutral | +1.4% | Inducement stock option grants to new employees under Nasdaq rules. |
Recent clinical and licensing updates have mostly seen modest positive reactions, with one notable divergence where positive Phase 1 PK data coincided with a share price decline.
Over the last few months, Sagimet reported several milestones. On Dec 18, 2025, positive Phase 1 PK data for the denifanstat–resmetirom combination led to a -4.94% move, diverging from constructive clinical news. A day earlier, a global license deal for resmetirom API forms saw shares rise 3.64%. December also brought China NDA acceptance for denifanstat in acne with small gains of 0.64%, and inducement grants on Dec 9, 2025 with a 1.45% uptick. Today’s conference-focused poster fits into a pattern of ongoing clinical development disclosures.
Market Pulse Summary
This announcement highlights additional visibility for denifanstat through a MASH-TAG 2026 poster describing anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients from the Phase 2b FASCINATE-2 trial. It builds on prior positive clinical and licensing updates over late 2025. Investors may watch for more granular efficacy and safety details, follow-on trial designs in advanced MASH, and how new data are integrated into future regulatory and partnering disclosures. The 52-week range of $1.73–$11.41 underscores existing volatility.
Key Terms
qfibrosis medical
phase 2b medical
fatty acid synthase (fasn) inhibitor medical
biomarkers medical
poster presentation technical
clinical trial medical
metabolic and fibrotic pathways medical
AI-generated analysis. Not financial advice.
SAN MATEO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that it will be presenting a poster at the upcoming 10th Annual MASH-TAG Conference being held January 8-10, 2026 in Park City, Utah. The poster will focus on the observed anti-fibrotic effects in F3 and qFibrosis stage 4 MASH patients in the Phase 2b FASCINATE-2 clinical trial of fatty acid synthase (FASN) inhibitor denifanstat.
MASH-TAG 2026 Poster Presentation Details:
| Title: | Denifanstat elicited a significant ≥2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of phase 2b FASCINATE-2 trial |
| Presenting Author: | Rohit Loomba, M.D., M.H.Sc., University of California San Diego |
| Poster number: | MASHTAG.2026.A23 |
| Date: | Saturday, January 10, 2026 |
| Location: | The Chateaux Deer Valley, Park City, Utah |
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. Denifanstat, an oral, once-daily pill, met all primary endpoints in its Phase 2b FASCINATE-2 clinical trial in MASH as well as all primary and secondary endpoints in Sagimet’s license partner for China’s Phase 3 clinical trial in moderate-to-severe acne. A combination of denifanstat and resmetirom was tested in a Phase 1 PK clinical trial and is planned to be developed for patients with MASH cirrhosis (F4). TVB-3567, a second oral FASN inhibitor which is planned to be developed for acne, is currently being tested in a Phase 1 first-in-human clinical trial. For additional information about Sagimet, please visit www.sagimet.com.
About MASH
MASH is a progressive and severe liver disease which is estimated to impact more than 265 million people worldwide. MASH is characterized by the build-up of fat in the liver and various degrees of inflammation and fibrosis along with systemic metabolic changes including dyslipidemia (increased fat levels in blood) and insulin resistance. Patients with moderate to severe disease who have advanced fibrosis (F3) or cirrhosis (F4) have the highest risk of liver-related outcomes such as decompensation, hepatocellular carcinoma, and liver transplantation. There are few approved treatments for non-cirrhotic MASH (stages F1, F2 and F3 fibrosis) and no approved treatments for MASH cirrhosis (F4).
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding: the expected timing of the presentation of data from ongoing clinical trials, Sagimet’s clinical development plans and related timelines and anticipated development milestones, Sagimet’s cash and financial resources and expected cash runway are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause Sagimet’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, these statements can be identified by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. Sagimet has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that Sagimet believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Sagimet’s control, including, among others: the clinical development and therapeutic potential of denifanstat, TVB-3567 or any other drug candidates or combination therapies developed by Sagimet; Sagimet’s ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines; Sagimet’s relationship with Ascletis, and the success of its development efforts for denifanstat; the accuracy of Sagimet’s estimates regarding its capital requirements; and Sagimet’s ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of Sagimet’s most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in these forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, Sagimet operates in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Sagimet may face. Except as required by applicable law, Sagimet does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Sagimet Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Sagimet Media Contact:
Michael Fitzhugh
LifeSci Advisors
mfitzhugh@lifescicomms.com
FAQ
What is Sagimet (SGMT) presenting at MASH-TAG 2026?
When and where will Sagimet's (SGMT) poster be presented at MASH-TAG 2026?
Who is the presenting author for Sagimet's (SGMT) MASH-TAG 2026 poster?
What trial and drug are discussed in the Sagimet (SGMT) MASH-TAG 2026 poster?
What clinical outcomes does the Sagimet (SGMT) poster report for denifanstat?
